JPH025730B2 - - Google Patents

Info

Publication number: JPH025730B2
Authority: JP; Japan
Prior art keywords: group; present; therapeutic agent; diabetic; phenyl ketone
Prior art date: 1981-01-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP45981A

Other languages

English (en)

Japanese (ja)

Other versions

JPS57114509A (en

Inventor

Hideki Ono

Toshinobu Kunii

Tsuneo Wakabayashi

Toshiji Oosato

Tadashi Sato

Kengo Kagei

Junichi Hase

Noboru Nakai

Keiichi Nomura

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-01-07

Filing date

1981-01-07

Publication date

1990-02-05

1981-01-07 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1981-01-07 Priority to JP45981A priority Critical patent/JPS57114509A/ja

1982-07-16 Publication of JPS57114509A publication Critical patent/JPS57114509A/ja

1990-02-05 Publication of JPH025730B2 publication Critical patent/JPH025730B2/ja

Status Granted legal-status Critical Current

Links

-1 p-hydroxyphenyl group Chemical group 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 10
206010007749 Cataract diabetic Diseases 0.000 claims description 8
201000007025 diabetic cataract Diseases 0.000 claims description 8
229940124597 therapeutic agent Drugs 0.000 claims description 8
239000003889 eye drop Substances 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 3
210000000695 crystalline len Anatomy 0.000 description 14
238000000034 method Methods 0.000 description 11
230000000694 effects Effects 0.000 description 10
208000002177 Cataract Diseases 0.000 description 9
241000700159 Rattus Species 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 8
102000016912 Aldehyde Reductase Human genes 0.000 description 6
108010053754 Aldehyde reductase Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
238000010998 test method Methods 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229940012356 eye drops Drugs 0.000 description 4
239000008103 glucose Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
231100000111 LD50 Toxicity 0.000 description 3
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000002651 drug therapy Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
239000006196 drop Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OKJFKPFBSPZTAH-UHFFFAOYSA-N (2,4-dihydroxyphenyl)-(4-hydroxyphenyl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O OKJFKPFBSPZTAH-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
102000014824 Crystallins Human genes 0.000 description 1
108010064003 Crystallins Proteins 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical class C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
125000004464 hydroxyphenyl group Chemical group 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000012085 test solution Substances 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP45981A 1981-01-07 1981-01-07 Remedy for diabetic cataract Granted JPS57114509A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP45981A JPS57114509A (en)	1981-01-07	1981-01-07	Remedy for diabetic cataract

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP45981A JPS57114509A (en)	1981-01-07	1981-01-07	Remedy for diabetic cataract

Publications (2)

Publication Number	Publication Date
JPS57114509A JPS57114509A (en)	1982-07-16
JPH025730B2 true JPH025730B2 (de)	1990-02-05

Family

ID=11474379

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP45981A Granted JPS57114509A (en)	1981-01-07	1981-01-07	Remedy for diabetic cataract

Country Status (1)

Country	Link
JP (1)	JPS57114509A (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7780235B2 (ja) *	2023-07-24	2025-12-04	国立大学法人大分大学	抗酸化化合物

1981
- 1981-01-07 JP JP45981A patent/JPS57114509A/ja active Granted

Also Published As

Publication number	Publication date
JPS57114509A (en)	1982-07-16

Publication	Publication Date	Title
JP2683676B2 (ja)	1997-12-03	局所投与用炎症性疾患治療剤
EP2163548B1 (de)	2011-08-10	Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration
US5547993A (en)	1996-08-20	Therapeutic agent for glaucoma
JPS62178514A (ja)	1987-08-05	眼局所投与用眼圧降下剤
EP0771563B1 (de)	2003-01-22	Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
SE467909B (sv)	1992-10-05	Anvaendning av komposition innehaallande fenylaettiksyraderivat foer framstaellning av ett laekemedel foer okulaer inflammation
US5506241A (en)	1996-04-09	Argatroban preparations for ophthalmic use
HU214719B (hu)	1998-05-28	Eljárás retinális betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
JPH025730B2 (de)	1990-02-05
EP1121110B1 (de)	2003-08-20	Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
AU677860B2 (en)	1997-05-08	Composition for prophylaxis and treatment of myopia
US20070299119A1 (en)	2007-12-27	Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy
WO1993023032A1 (fr)	1993-11-25	Remede contre la cataracte et procede de production associe
EA029157B1 (ru)	2018-02-28	Терапия макулярной дегенерации на основе баклофена и акампросата
US20060287394A1 (en)	2006-12-21	Composition and method for treating macular disorders
JPS62234018A (ja)	1987-10-14	糖尿病併発症治療剤
KR20220166203A (ko)	2022-12-16	퇴행성 안질환의 예방 또는 치료용 약학적 조성물
CN113041217A (zh)	2021-06-29	一种含环糊精或环糊精衍生物的石杉碱甲水溶性滴眼液及其制备方法和应用
WO2010010939A1 (ja)	2010-01-28	加齢黄斑変性の予防又は治療剤
CA1279015C (en)	1991-01-15	Increasing aqueous humor outflow
CN111700898B (zh)	2021-07-13	巴戟甲素的应用
TW461815B (en)	2001-11-01	Pharmaceutical composition for improvement of the optic nerve head circulation
JPS6348215A (ja)	1988-02-29	糖尿病性合併症治療剤
WO2009110526A1 (ja)	2009-09-11	３’，５－ジ－２－プロペニル－（１，１’－ビフェニル）－２，４’－ジオールを有効成分として含有する視神経障害の予防又は治療剤
JP3612618B2 (ja)	2005-01-19	網膜疾患治療剤